Skip to main content

Table 4 Exclusivity for the first generic market entrant

From: Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States

 

United States

Canada

Australia

South Korea

Small molecules

Biologics

Requirements for exclusivity

be the first ANDA applicant arguing paragraph IV

N/A

N/A

–

(1) the first ANDA that has challenged a patent and obtained a favorable decision; or

(2) the first ANDA that has filed a challenge within 14 days of the first challenge and has become the first to obtain a favorable decision

(3) filed a challenge within 14 days of the first challenge and become the first to obtain a favourable decision

Specific measures

180-day exclusivity

N/A

N/A

N/A

9-month exclusivity, additional 2-month period is available to compensate for delayed marketing due to the reimbursement process

A starting point of the measures

the date of the first commercial marketing

N/A

N/A

N/A

the date of the marketing